Hematology

Study identifies potential Achilles heel of kinase-driven cancers.

Treatment with endostatin slowed the proliferation of resistant prostate cancer cells.

Most models were cancer-free within 6 weeks of treatment with selenomab-drug conjugates.

Next-generation antibody treatments effectively deliver cytotoxic drugs to tumors.

Corticosteroids, chemotherapy, and immunotherapy may all be used to treat castration-resistant prostate cancer.

Top news of the week in oncology and cancer drug development.

Checkpoint inhibitors plus myeloid-derived suppressor cell inhibitors show promise as prostate cancer treatment.

Quiescent stem cells are dormant and are not impacted by cancer treatments.

The addition of abemaciclib to fulvestrant appeared to effectively improve progression-free survival in patients with breast cancer.

The addition of abemaciclib to fulvestrant appeared to effectively improve progression-free survival.

High yogurt intake may protect against breast cancer, while processed cheeses may increase cancer risk.

Mapping lung cancer cell interactions can unveil new targeted treatment techniques.

Vitamin C observed to kill cancer stem-like cells.

Nanomachines produce a florescent response when in contact with cancer biomarkers.

Muscle composition may be predictive of chemotherapy toxicity.

Clinical practice guideline on human papillomavirus (HPV) vaccination can improve prevention of cervical cancer.

The risk of a second cancer remained high even 30 years after treatment.

Top news of the week in oncology and cancer drug development.

Researchers analyzed tumors and treated them with a targeted therapy.

A combination drug regimen may be the answer to treating acute myeloid leukemia.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

BET-inhibitors and immune-based treatments may improve outcomes in patients with blood cancer.

Patients with specific stem cell mutations may be at an increased risk of acute myeloid leukemia.

Protein once thought to suppress tumors in acute myeloid leukemia may instead promote the disease.